[Skip to Navigation]
Sign In

May 2022 - July 1959

Decade

Year

Issue

June 2022, Vol 79, No. 6, Pages 536-634

Viewpoint

The Global Burden of Polyneuropathy—In Need of an Accurate Assessment

Abstract Full Text
JAMA Neurol. 2022;79(6):537-538. doi:10.1001/jamaneurol.2022.0565

This Viewpoint discusses the patient morbidity and global financial health care cost of polyneuropathy.

Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology

Abstract Full Text
JAMA Neurol. 2022;79(6):539-540. doi:10.1001/jamaneurol.2022.0769

This Viewpoint advocates for the field of neurology to spearhead advancements in prevention, recognition, and treatment of toxic stress and associated health impacts following trauma and adverse childhood experiences.

On the Brain

The Road Not Taken

Abstract Full Text
JAMA Neurol. 2022;79(6):541. doi:10.1001/jamaneurol.2022.0297

This essay describes the author’s experience with having a stroke.

Editorial

Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management

Abstract Full Text
JAMA Neurol. 2022;79(6):542-543. doi:10.1001/jamaneurol.2022.0092
Original Investigation

Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19

Abstract Full Text
free access has active quiz has audio
JAMA Neurol. 2022;79(6):544-553. doi:10.1001/jamaneurol.2022.0154

This cohort study evaluates the association of COVID-19 infection with olfactory bulb by performing an ultrastructural and histopathological analysis of patients with COVID-19 and age- and disease severity–compatible controls.

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Neurol. 2022;79(6):554-564. doi:10.1001/jamaneurol.2022.0829

This randomized clinical trial examines the change from baseline in drop seizure frequency, response rates, and improvement on the Clinical Global Impression scale among patients with Lennox-Gastaut syndrome.

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial

Abstract Full Text
JAMA Neurol. 2022;79(6):565-574. doi:10.1001/jamaneurol.2022.0983

This phase 1b randomized clinical trial assesses the safety and tolerability of the antiamyloid ACI-24 vaccine and investigates the vaccine’s ability to induce immunogenicity among adults with Down syndrome at risk of developing a genetic form of Alzheimer disease.

Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial

Abstract Full Text
JAMA Neurol. 2022;79(6):575-583. doi:10.1001/jamaneurol.2022.0901

This randomized clinical trial showed that use of ultrahigh-dose methylcobalamin in Japanese patients in the early stages of amyotrophic lateral sclerosis with moderate progression can slow functional decline and had a good safety profile.

Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US

Abstract Full Text
JAMA Neurol. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976

This cross-sectional study evaluates modifiable risk factors associated with Alzheimer disease and related dementias in the US and assesses risk differences by sex and race and ethnicity.

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease

Abstract Full Text
JAMA Neurol. 2022;79(6):592-603. doi:10.1001/jamaneurol.2022.0676

This cross-sectional study evaluates the prevalence of cortical tau positron emission tomography heterogeneity in a large cohort of clinically unimpaired older adults with elevated β-amyloid.

Prediction of Long-term Survival After Status Epilepticus Using the ACD Score

Abstract Full Text
JAMA Neurol. 2022;79(6):604-613. doi:10.1001/jamaneurol.2022.0609

This cohort study uses a new 3-factor scoring system to estimate long-term outcomes in patients who experienced status epilepticus.

Noninvasive Detection of Hippocampal Epileptiform Activity on Scalp Electroencephalogram

Abstract Full Text
JAMA Neurol. 2022;79(6):614-622. doi:10.1001/jamaneurol.2022.0888

This diagnostic study investigates whether a computer algorithm can be trained to detect hippocampal epileptiform activity on scalp electroencephalogram without the need for intracranial electrodes.

Brief Report

Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US

Abstract Full Text
JAMA Neurol. 2022;79(6):623-626. doi:10.1001/jamaneurol.2022.0723

Using data from the Health and Retirement Study, this cross-sectional study assesses whether vision impairment should be included in a life-course model of potentially modifiable dementia risk factors.

Images in Neurology

Sleep Recording for the Diagnosis and Treatment of Paraplegia

Abstract Full Text
has active quiz has multimedia
JAMA Neurol. 2022;79(6):627. doi:10.1001/jamaneurol.2022.0619

This case report describes a woman in her 30s with functional paraplegia who was diagnosed and treated by video polysomnography.

Photon-Counting Computed Tomography Scan of a Cerebrospinal Fluid Venous Fistula

Abstract Full Text
has active quiz has multimedia
JAMA Neurol. 2022;79(6):628-629. doi:10.1001/jamaneurol.2022.0687

This case report describes the use of traditional computed tomography vs photon-counting computed tomography in evaluating the potential cause of spontaneous intracranial hypotension in a 56-year-old female patient.

JAMA Neurology Clinical Challenge

Progressive Parkinsonism With Features of Mitochondrial Disease

Abstract Full Text
has active quiz has multimedia
JAMA Neurol. 2022;79(6):630-631. doi:10.1001/jamaneurol.2022.0920

A man aged 44 years presented with progressive parkinsonism and poor levodopa response. His medical history included unexplained sensory hearing loss, hyperlipidemia, osteoarthritis, and walking difficulty with frequent falls. What is your diagnosis?

Comment & Response

Blood Biomarkers May Have Found a New Frontier in Spaceflight

Abstract Full Text
JAMA Neurol. 2022;79(6):632. doi:10.1001/jamaneurol.2022.0670

Blood Biomarkers May Have Found a New Frontier in Spaceflight—Reply

Abstract Full Text
JAMA Neurol. 2022;79(6):632-633. doi:10.1001/jamaneurol.2022.0673

Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities

Abstract Full Text
JAMA Neurol. 2022;79(6):633-634. doi:10.1001/jamaneurol.2022.0731

Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities—Reply

Abstract Full Text
JAMA Neurol. 2022;79(6):634. doi:10.1001/jamaneurol.2022.0734
Correction

Error in Figure 2

Abstract Full Text
free access
JAMA Neurol. 2022;79(6):634. doi:10.1001/jamaneurol.2022.1401

Errors in the Text and Key Points

Abstract Full Text
free access
JAMA Neurol. 2022;79(6):634. doi:10.1001/jamaneurol.2022.1557
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2022;79(6):536. doi:10.1001/jamaneurol.2021.3773
×